Potassium modification of the somatostatin effect on stimulated rat growth hormone release

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Experiments were designed to study the inhibitory action of somatostatin (SRIF) on stimulated GH release. The studies were performed in a standard incubation- or perifusion- immunoprecipitation system in which rat anterior pituitaries were prelabeled with [3H]leucine to define a pool of stored rat GH ([3H]GH) whose temporal release could be followed separate from any contribution by new hormone synthesis. The responses to 1CT3 M dibutyryl cAMP (dbcAMP), to the depolarizing effect of 21 mM potassium ion (K+), to a maximally inhibitory concentration of SRIF (25 nM), and to the three in various combinations were defined. Stimulation of initial [3H]GH release above basal (0.065%/min) was immediate and rapid after either K+ (0.45%/min) or dbcAMP (0.37%/min); used together, the releasing effect of these two agents was almost additive (0.69%/min). However, while the K+ response was complete in 30—40 min, an increased rate of release in response to dbcAMP (0.24%/min) was sustained for the duration of that stimulus. Maximal SRIF prevented dbcAMP or K+ stimulation of [3H]GH release above pre-SRIF basal release rates (0.068%/miri), but despite maximal SRIF, the combination of dbcAMP and K+ stimulated [3H]GH release in a biphasic pattern (initial, 0.35%/min; sustained, 0.25%/min) similar to that produced by dbcAMP alone in the absence of SRIF. The interrelation of SRIF, K+, and dbcAMP effects upon [3H]GH release was further studied in pituitary explants which had been pretreated by exposure to SRIF plus dbcAMP, SRIF plus K+, or SRIF plus both K+ and dbcAMP. In each pretreated group, SRIF was withdrawn and [3H]GH release examined during dbcAMP, K+, or dbcAMP plus K+ stimulation and in the absence of stimulation. SRIF withdrawal after pretreatment by SRIF plus K+ resulted in no rebound [3H]rGH release, an absence of the immediate release response to dbcAMP stimulation, but persistence of K+-induced immediate release (0.33%/min) which could be enhanced by the addition of dbcAMP (0.60%/min overall). After SRIF plus dbcAMP pretreatment, immediate rebound release of [3H]GH followed SRIF withdrawal (0.25%/min), and stimulation by dbcAMP (0.59%/min), K+ (0.88%/min), or both together (1.05%/min) enhanced that immediate release. SRIF withdrawal after pretreatment with SRIF plus both K+ and dbcAMP resulted in a similar enhancement of rebound [3H]GH release (0.37%/min), combined K+ and dbcAMP stimulating more rapid [3H]GH release (1.29%/min) than did any other protocol. In conclusion: 1) in resting and stimulated explants, SRIF may inhibit stored [3H]GH release by more than one mechanism, 2) the immediate/brief phase of dbcAMP-stimulated [3H]GH release can be eliminated despite persistence of the late/sustained phase of dbcAMP-stimulated release, 3) depolarizing concentrations of K+ interfere with the inhibitory effect of SRIF upon dbcAMP-stimulated [3H]GH release, and 4) the immediately releasable pool of [3H]GH has both dbcAMP- and K+- sensitive components which overlap and whose content can be increased by the accumulation of stored hormone behing a SRIF block.

Original languageEnglish (US)
Pages (from-to)1027-1034
Number of pages8
JournalEndocrinology
Volume108
Issue number3
DOIs
StatePublished - Jan 1 1981

Fingerprint

Somatostatin
Growth Hormone
Potassium
Hormones
Immunoprecipitation
Leucine
Ions

ASJC Scopus subject areas

  • Endocrinology

Cite this

Potassium modification of the somatostatin effect on stimulated rat growth hormone release. / Stachura, M. E.

In: Endocrinology, Vol. 108, No. 3, 01.01.1981, p. 1027-1034.

Research output: Contribution to journalArticle

@article{0a85d3f6c8674a3aa73c975ac7e433a0,
title = "Potassium modification of the somatostatin effect on stimulated rat growth hormone release",
abstract = "Experiments were designed to study the inhibitory action of somatostatin (SRIF) on stimulated GH release. The studies were performed in a standard incubation- or perifusion- immunoprecipitation system in which rat anterior pituitaries were prelabeled with [3H]leucine to define a pool of stored rat GH ([3H]GH) whose temporal release could be followed separate from any contribution by new hormone synthesis. The responses to 1CT3 M dibutyryl cAMP (dbcAMP), to the depolarizing effect of 21 mM potassium ion (K+), to a maximally inhibitory concentration of SRIF (25 nM), and to the three in various combinations were defined. Stimulation of initial [3H]GH release above basal (0.065{\%}/min) was immediate and rapid after either K+ (0.45{\%}/min) or dbcAMP (0.37{\%}/min); used together, the releasing effect of these two agents was almost additive (0.69{\%}/min). However, while the K+ response was complete in 30—40 min, an increased rate of release in response to dbcAMP (0.24{\%}/min) was sustained for the duration of that stimulus. Maximal SRIF prevented dbcAMP or K+ stimulation of [3H]GH release above pre-SRIF basal release rates (0.068{\%}/miri), but despite maximal SRIF, the combination of dbcAMP and K+ stimulated [3H]GH release in a biphasic pattern (initial, 0.35{\%}/min; sustained, 0.25{\%}/min) similar to that produced by dbcAMP alone in the absence of SRIF. The interrelation of SRIF, K+, and dbcAMP effects upon [3H]GH release was further studied in pituitary explants which had been pretreated by exposure to SRIF plus dbcAMP, SRIF plus K+, or SRIF plus both K+ and dbcAMP. In each pretreated group, SRIF was withdrawn and [3H]GH release examined during dbcAMP, K+, or dbcAMP plus K+ stimulation and in the absence of stimulation. SRIF withdrawal after pretreatment by SRIF plus K+ resulted in no rebound [3H]rGH release, an absence of the immediate release response to dbcAMP stimulation, but persistence of K+-induced immediate release (0.33{\%}/min) which could be enhanced by the addition of dbcAMP (0.60{\%}/min overall). After SRIF plus dbcAMP pretreatment, immediate rebound release of [3H]GH followed SRIF withdrawal (0.25{\%}/min), and stimulation by dbcAMP (0.59{\%}/min), K+ (0.88{\%}/min), or both together (1.05{\%}/min) enhanced that immediate release. SRIF withdrawal after pretreatment with SRIF plus both K+ and dbcAMP resulted in a similar enhancement of rebound [3H]GH release (0.37{\%}/min), combined K+ and dbcAMP stimulating more rapid [3H]GH release (1.29{\%}/min) than did any other protocol. In conclusion: 1) in resting and stimulated explants, SRIF may inhibit stored [3H]GH release by more than one mechanism, 2) the immediate/brief phase of dbcAMP-stimulated [3H]GH release can be eliminated despite persistence of the late/sustained phase of dbcAMP-stimulated release, 3) depolarizing concentrations of K+ interfere with the inhibitory effect of SRIF upon dbcAMP-stimulated [3H]GH release, and 4) the immediately releasable pool of [3H]GH has both dbcAMP- and K+- sensitive components which overlap and whose content can be increased by the accumulation of stored hormone behing a SRIF block.",
author = "Stachura, {M. E.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1210/endo-108-3-1027",
language = "English (US)",
volume = "108",
pages = "1027--1034",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Potassium modification of the somatostatin effect on stimulated rat growth hormone release

AU - Stachura, M. E.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Experiments were designed to study the inhibitory action of somatostatin (SRIF) on stimulated GH release. The studies were performed in a standard incubation- or perifusion- immunoprecipitation system in which rat anterior pituitaries were prelabeled with [3H]leucine to define a pool of stored rat GH ([3H]GH) whose temporal release could be followed separate from any contribution by new hormone synthesis. The responses to 1CT3 M dibutyryl cAMP (dbcAMP), to the depolarizing effect of 21 mM potassium ion (K+), to a maximally inhibitory concentration of SRIF (25 nM), and to the three in various combinations were defined. Stimulation of initial [3H]GH release above basal (0.065%/min) was immediate and rapid after either K+ (0.45%/min) or dbcAMP (0.37%/min); used together, the releasing effect of these two agents was almost additive (0.69%/min). However, while the K+ response was complete in 30—40 min, an increased rate of release in response to dbcAMP (0.24%/min) was sustained for the duration of that stimulus. Maximal SRIF prevented dbcAMP or K+ stimulation of [3H]GH release above pre-SRIF basal release rates (0.068%/miri), but despite maximal SRIF, the combination of dbcAMP and K+ stimulated [3H]GH release in a biphasic pattern (initial, 0.35%/min; sustained, 0.25%/min) similar to that produced by dbcAMP alone in the absence of SRIF. The interrelation of SRIF, K+, and dbcAMP effects upon [3H]GH release was further studied in pituitary explants which had been pretreated by exposure to SRIF plus dbcAMP, SRIF plus K+, or SRIF plus both K+ and dbcAMP. In each pretreated group, SRIF was withdrawn and [3H]GH release examined during dbcAMP, K+, or dbcAMP plus K+ stimulation and in the absence of stimulation. SRIF withdrawal after pretreatment by SRIF plus K+ resulted in no rebound [3H]rGH release, an absence of the immediate release response to dbcAMP stimulation, but persistence of K+-induced immediate release (0.33%/min) which could be enhanced by the addition of dbcAMP (0.60%/min overall). After SRIF plus dbcAMP pretreatment, immediate rebound release of [3H]GH followed SRIF withdrawal (0.25%/min), and stimulation by dbcAMP (0.59%/min), K+ (0.88%/min), or both together (1.05%/min) enhanced that immediate release. SRIF withdrawal after pretreatment with SRIF plus both K+ and dbcAMP resulted in a similar enhancement of rebound [3H]GH release (0.37%/min), combined K+ and dbcAMP stimulating more rapid [3H]GH release (1.29%/min) than did any other protocol. In conclusion: 1) in resting and stimulated explants, SRIF may inhibit stored [3H]GH release by more than one mechanism, 2) the immediate/brief phase of dbcAMP-stimulated [3H]GH release can be eliminated despite persistence of the late/sustained phase of dbcAMP-stimulated release, 3) depolarizing concentrations of K+ interfere with the inhibitory effect of SRIF upon dbcAMP-stimulated [3H]GH release, and 4) the immediately releasable pool of [3H]GH has both dbcAMP- and K+- sensitive components which overlap and whose content can be increased by the accumulation of stored hormone behing a SRIF block.

AB - Experiments were designed to study the inhibitory action of somatostatin (SRIF) on stimulated GH release. The studies were performed in a standard incubation- or perifusion- immunoprecipitation system in which rat anterior pituitaries were prelabeled with [3H]leucine to define a pool of stored rat GH ([3H]GH) whose temporal release could be followed separate from any contribution by new hormone synthesis. The responses to 1CT3 M dibutyryl cAMP (dbcAMP), to the depolarizing effect of 21 mM potassium ion (K+), to a maximally inhibitory concentration of SRIF (25 nM), and to the three in various combinations were defined. Stimulation of initial [3H]GH release above basal (0.065%/min) was immediate and rapid after either K+ (0.45%/min) or dbcAMP (0.37%/min); used together, the releasing effect of these two agents was almost additive (0.69%/min). However, while the K+ response was complete in 30—40 min, an increased rate of release in response to dbcAMP (0.24%/min) was sustained for the duration of that stimulus. Maximal SRIF prevented dbcAMP or K+ stimulation of [3H]GH release above pre-SRIF basal release rates (0.068%/miri), but despite maximal SRIF, the combination of dbcAMP and K+ stimulated [3H]GH release in a biphasic pattern (initial, 0.35%/min; sustained, 0.25%/min) similar to that produced by dbcAMP alone in the absence of SRIF. The interrelation of SRIF, K+, and dbcAMP effects upon [3H]GH release was further studied in pituitary explants which had been pretreated by exposure to SRIF plus dbcAMP, SRIF plus K+, or SRIF plus both K+ and dbcAMP. In each pretreated group, SRIF was withdrawn and [3H]GH release examined during dbcAMP, K+, or dbcAMP plus K+ stimulation and in the absence of stimulation. SRIF withdrawal after pretreatment by SRIF plus K+ resulted in no rebound [3H]rGH release, an absence of the immediate release response to dbcAMP stimulation, but persistence of K+-induced immediate release (0.33%/min) which could be enhanced by the addition of dbcAMP (0.60%/min overall). After SRIF plus dbcAMP pretreatment, immediate rebound release of [3H]GH followed SRIF withdrawal (0.25%/min), and stimulation by dbcAMP (0.59%/min), K+ (0.88%/min), or both together (1.05%/min) enhanced that immediate release. SRIF withdrawal after pretreatment with SRIF plus both K+ and dbcAMP resulted in a similar enhancement of rebound [3H]GH release (0.37%/min), combined K+ and dbcAMP stimulating more rapid [3H]GH release (1.29%/min) than did any other protocol. In conclusion: 1) in resting and stimulated explants, SRIF may inhibit stored [3H]GH release by more than one mechanism, 2) the immediate/brief phase of dbcAMP-stimulated [3H]GH release can be eliminated despite persistence of the late/sustained phase of dbcAMP-stimulated release, 3) depolarizing concentrations of K+ interfere with the inhibitory effect of SRIF upon dbcAMP-stimulated [3H]GH release, and 4) the immediately releasable pool of [3H]GH has both dbcAMP- and K+- sensitive components which overlap and whose content can be increased by the accumulation of stored hormone behing a SRIF block.

UR - http://www.scopus.com/inward/record.url?scp=0019475428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019475428&partnerID=8YFLogxK

U2 - 10.1210/endo-108-3-1027

DO - 10.1210/endo-108-3-1027

M3 - Article

VL - 108

SP - 1027

EP - 1034

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -